The laboratory information system market has long been dominated by legacy platforms built for a different era of pathology. These systems were designed around physical specimens, manual data entry, and workflows that assumed a pathologist would be sitting in the same building as the slides they were reading. For years, labs largely accepted this reality as the cost of doing business in a highly specialized field.
NovoPath is changing that assumption, and the disruption is becoming difficult to ignore.
With a focused platform purpose-built for anatomic pathology and an accelerating investment in digital pathology capabilities, NovoPath is repositioning what a laboratory information system can actually do. It is not simply offering a better version of what already exists. It is advancing a fundamentally different idea of where the LIS sits in the modern lab, and what role it should play as artificial intelligence and whole slide imaging become central to how diagnoses are made.
The Problem with the Legacy LIS Market
To understand why NovoPath is gaining ground, it helps to understand the market it is disrupting. Traditional laboratory information systems were engineered primarily as data management and reporting tools. They tracked specimens, stored results, and generated reports. For labs operating in an analog environment, this was sufficient. The pathologist looked through a microscope, dictated a diagnosis, and the system captured and transmitted it.
The shift to digital pathology has exposed the limitations of this model in a direct and costly way. As labs began adopting whole slide imaging, they often found their existing LIS platforms simply could not accommodate the new workflow. Digital slide viewers operated as entirely separate systems. Pathologists were forced to toggle between platforms, manually reconciling case data with image data, reconstructing context that should have been unified from the start.
These viewer-first architectures, where the digital viewer exists alongside core laboratory systems rather than within them, create fragmentation at the point where consistency matters most. Cases are accessed in one system, images are reviewed in another, and workflow logic is distributed across tools. The downstream effects are real: slower turnaround times, higher error risk, and a digital pathology investment that never fully delivers on its operational promise.
NovoPath identified this gap and built toward it deliberately.
NovoPath 360: A Platform Built Around the Pathologist’s Actual Workflow
The centerpiece of NovoPath’s market position is NovoPath 360, a cloud-based LIS delivered as a software-as-a-service platform and backed by Microsoft’s cloud infrastructure. The design philosophy behind it differs meaningfully from legacy competitors in one important respect: it treats digital pathology not as an add-on module, but as a core function of the system.
NovoPath’s digital pathology solution allows seamless access to digital images within the NovoPath 360 LIS via robust integration with preferred viewers, synchronizing reporting, imaging, and case management in real time so pathologists can review, analyze, and finalize cases from a single centralized system without redundant steps or manual input.
This integration matters more than it might initially appear. When the image and the case record exist in the same operational environment, the pathologist never loses context. Prior history is surfaced automatically. Collaboration happens within the same system where sign-out occurs. The cognitive overhead that accumulates when clinicians are forced to work across disconnected tools is eliminated, and what remains is a cleaner, faster path from specimen receipt to final report.
NovoPath 360 provides a comprehensive view of each case, stage, and operation, allowing labs to easily track turnaround times, workloads, errors, and bottlenecks within the lab workflow to reduce errors and operational inefficiencies. For lab directors managing complex, high-volume environments, this kind of real-time operational visibility is a meaningful differentiator from platforms that offer only retrospective reporting.
A Workflow-First Approach to Digital Pathology
One of the more substantive intellectual contributions NovoPath has made to the digital pathology conversation is its articulation of a workflow-first design philosophy, which stands in contrast to the viewer-first approach that has characterized many labs’ early digital investments.
Workflow-first digital pathology begins with a different question. Instead of asking how images should be viewed, it asks how diagnostic work actually flows through the lab, including how cases move from accession to sign-out, how prior history is surfaced during review, how collaboration occurs, and how decisions are captured and governed.
This framing has practical consequences. Labs that organized their digital pathology investments around the viewer often find that scaling becomes difficult and introducing AI later requires significant re-architecture. Labs that organize around workflow, with the LIS as the central operating system and the viewer as one component within it, build an environment that can accommodate AI tools, remote pathologists, and expanding case volumes without requiring a rebuild.
Labs that prioritize workflow alignment build environments that pathologists trust, operations teams can govern, and AI initiatives can build upon. This is not a minor technical point. As AI becomes a real operational consideration in pathology labs, the architectural decisions that labs make today will determine how easily they can take advantage of those capabilities tomorrow.
Enabling Telepathology and Remote Diagnostics
The workforce dynamics of anatomic pathology are under pressure. Demand for diagnostic services is rising, the pipeline of trained pathologists is not expanding at the same pace, and geographic distribution of expertise remains highly uneven. Digital pathology, when implemented correctly, offers a structural solution to all three problems. But only when the underlying platform is capable of supporting genuine remote workflows rather than simply allowing images to be accessed from off-site.
NovoPath enables real-time telepathology by allowing pathologists to review digital slides instantly regardless of location, helping labs expand expertise without hiring additional staff, speed up complex case reviews, and improve patient care through faster decision-making.
For labs operating across multiple sites, or for smaller independent labs that want access to subspecialty expertise without the cost of additional full-time hires, this capability directly changes the economics of how pathology services can be delivered. A lab in a smaller market can consult with a specialized pathologist across the country without shipping a physical slide, waiting for it to arrive, and then waiting again for it to be returned. The entire cycle compresses.
With whole slide images, it is easy to consult with pathologists worldwide, eliminating the need to ship physical slides to consultants and enabling faster diagnoses. Tumor board preparation, which requires time-consuming physical slide preparation, is also simplified through digital slide sharing with attendees.
Platform Agnosticism as a Competitive Advantage
One of the more strategically significant decisions NovoPath has made is to build its digital pathology infrastructure as platform-agnostic. In a market where many vendors attempt to lock customers into proprietary ecosystems, NovoPath’s openness to integration with any digital viewer, instrument, or third-party system that supports LIS integration is a meaningful point of differentiation.
NovoPath’s digital pathology system is platform-agnostic, seamlessly integrating with any digital viewer, instrument, or third-party system that supports LIS integration. This matters for labs that have already made investments in specific scanners or viewers and do not want to abandon those investments to adopt a new LIS. It also matters as the AI tool ecosystem continues to develop, since labs will want the flexibility to evaluate and adopt AI applications without being constrained by their infrastructure.
NovoPath is a pioneer in the space by being one of the first commercial LIS platforms to integrate with a whole slide imager, specifically the Philips IntelliSite at IDEXX, a milestone that established early credibility in the digital pathology integration space.
This early commitment to integration, paired with over 30 years of experience serving complex anatomic pathology labs, gives NovoPath a depth of workflow knowledge that newer entrants to the market cannot replicate quickly.
Tackling the Reimbursement Challenge Head-On
One area where NovoPath is taking a notably proactive position in 2026 involves the complex reimbursement landscape around digital pathology. As CMS has created monitoring codes to track utilization of digitized slides, labs have faced a frustrating dynamic: reimbursement for digital pathology workflows remains limited in part because reported utilization appears low, but utilization appears low in part because the tools required to accurately capture and report it are not built into most LIS platforms.
NovoPath positions its LIS as a digital pathology reporting engine, integrating with major digital viewers, automatically identifying digitally-read cases, surfacing the correct CPT add-on codes, and pushing clean data into revenue cycle management systems so labs can report accurately without burning out staff.
This is a practical and significant capability. Labs that cannot easily document which cases were read digitally cannot claim the add-on codes that reflect that work. Over time, this underreporting suppresses the utilization data that CMS uses to evaluate whether permanent reimbursement is warranted. NovoPath’s approach turns the LIS into an active participant in building the case for broader digital pathology reimbursement, not just a passive record-keeping system.
The core perspective NovoPath has articulated is that the LIS should not just store data; it should actively help labs prove digital adoption to CMS and payers without creating additional administrative burden for staff.
Scaling Without Proportional Headcount Growth
Among the most tangible outcomes that labs report after implementing NovoPath is the ability to handle significant case volume growth without a corresponding increase in staffing. In an environment where labor costs are rising and qualified pathology staff are difficult to recruit, this is not a marginal improvement. It is a structural advantage.
One lab reported a 30% increase in case volume without needing to bring on additional staff, attributing that capacity to the operational efficiencies created by NovoPath’s LIS platform.
This kind of outcome is made possible by automation built into the case lifecycle. Label printing, workload distribution, reflex testing rules, and QA flagging all happen according to configured logic rather than manual intervention. The result is that staff time is directed toward tasks that genuinely require human judgment, and the system handles the coordination and routing that previously consumed significant administrative bandwidth.
What NovoPath Represents for the Broader Market
The disruption NovoPath is introducing to the lab management software market is not primarily about any single feature. It is about a coherent point of view on where the market is heading and a platform architecture built to deliver on that view.
The laboratory information system of the past was a record-keeping tool. The LIS of the present and future is an operational hub, one that connects imaging, clinical data, AI tools, remote pathologists, billing systems, and compliance reporting into a unified environment. Legacy platforms built for the former role are struggling to become the latter. NovoPath started closer to where the market is going, and that starting position is proving to be a durable advantage.
As digital pathology becomes standard practice rather than an early-adopter distinction, and as AI tools move from pilot projects to clinical operations, the labs that will be best positioned are those whose core software infrastructure was designed with both in mind. NovoPath is building toward that future deliberately, and the lab management software market is beginning to take notice.